
Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders, has raised $59 million in Series A financing. Sofinnova Partners and Polaris Partners led the round.
Source: Press Release
Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders, has raised $59 million in Series A financing.
Noema Pharma, a Swiss clinical-stage company targeting orphan neurological disorders, has raised $59 million in Series A financing. Sofinnova Partners and Polaris Partners led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination